1. Ahn K, Meyer TH, Uebel S, Sempe S, Djaballah H, Yang Y, Peterson PA, Fruh K, Tampe R (1996) Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J 15: 3247–3255
2. Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton E, Wittek AE, Diaz PS (1986) Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol 137: 1346–1351
3. Arvin AM, Pollard RB, Ramussen LE, Merigan TC (1980) Cellular and humoral immunity in lymphoma patients. J Clin Invest 65: 869
4. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchongton P, Ruyechan W (1991) Equivalent recognition of a varicella-zoster virus immediate early protein (1E62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol 146: 257–264
5. Baudoux L, Defechereux P, Schoonbroodt S, Merville MP, Rentier B, Piette J (1995) Mutational analysis of varicella-zoster virus major immediate-early protein 1E62. Nucleic Acids Res 23: 1341–1349